pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

9 catalysts · 2 drug expiry · 2 patent expiry · 2 phase iv trial initiation · 1 phase 1 initiation · 1 phase 1 results · 1 phase 2 completion

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-10: 0 catalysts2026-08-11: 16 catalysts2026-08-12: 19 catalysts2026-08-13: 19 catalysts2026-08-14: 4 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 1 catalyst2026-08-18: 2 catalysts2026-08-19: 2 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 1 catalyst2026-08-27: 1 catalyst2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 1 catalyst2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 2 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 2 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 1 catalyst2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 1 catalyst2026-10-20: 2 catalysts2026-10-21: 2 catalysts2026-10-22: 2 catalysts2026-10-23: 1 catalyst2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 1 catalyst2026-10-27: 8 catalysts2026-10-28: 12 catalysts2026-10-29: 21 catalysts2026-10-30: 4 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts2026-11-02: 8 catalysts2026-11-03: 17 catalysts2026-11-04: 22 catalysts2026-11-05: 36 catalysts2026-11-06: 2 catalysts2026-11-07: 0 catalysts2026-11-08: 0 catalysts
view
agendamonth
sort
soonestlatesttypesponsoralpha
TA: ophthalmology×TA: infectious-disease×TA: immunology×to 2026-04-24×clear all
type
  • drug expiry2
  • patent expiry2
  • phase iv trial initiation2
  • phase 1 initiation1
  • phase 1 results1
phase 2 completion
1
therapy area
  • Oncology9
  • Infectious Disease5
  • Dermatology4
  • Pulmonology3
  • Women's Health3
  • Immunology3
  • Pain3
  • Ophthalmology1

Week of Apr 20, 2026

9
›Apr 24, 2026patent expiry109d agoDaiichi Sankyo Co Ltd — laninamivir (Constraining Patent Expiry (Japan))laninamivir

Therapy area: Infectious Disease, Respiratory. Indication: Asthma, Influenzavirus A Infections, Influenzavirus B Infections

full page →laninamivir →source: globaldata
›Apr 24, 2026patent expiry109d agoEisai Co Ltd — lenvatinib mesylate (Constraining Patent Expiry (US))lenvatinib mesylate

Therapy area: Gastrointestinal, Infectious Disease, Oncology. Indication: Acral Lentiginous Melanoma, Adenocarcinoma Of The Gastroesophageal Junction, Adenoid Cystic Carcinoma (ACC), Adrenocortical Carcinoma (Adrenal Cortex Cancer), Anaplastic Thyroid Cancer, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Breast Cancer, Colorectal Cancer, Cutaneous Squamous Cell Carcinoma (cSCC), Endometrial Cancer, Ependymoma, Epithelial Ovarian Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Ewing S

full page →lenvatinib mesylate →source: globaldata
›Apr 24, 2026drug expiry109d agoDaiichi Sankyo Co Ltd — laninamivir (Drug Expiry (Japan))laninamivir

Therapy area: Infectious Disease, Respiratory. Indication: Asthma, Influenzavirus A Infections, Influenzavirus B Infections

full page →laninamivir →source: globaldata
›Apr 24, 2026drug expiry109d agoEisai Co Ltd — lenvatinib mesylate (Drug Expiry (US))lenvatinib mesylate

Therapy area: Gastrointestinal, Infectious Disease, Oncology. Indication: Acral Lentiginous Melanoma, Adenocarcinoma Of The Gastroesophageal Junction, Adenoid Cystic Carcinoma (ACC), Adrenocortical Carcinoma (Adrenal Cortex Cancer), Anaplastic Thyroid Cancer, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Breast Cancer, Colorectal Cancer, Cutaneous Squamous Cell Carcinoma (cSCC), Endometrial Cancer, Ependymoma, Epithelial Ovarian Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Ewing S

full page →lenvatinib mesylate →source: globaldata
›Apr 24, 2026phase 1 initiation109d agoBeijing Friendship Hospital — CMSD-001 (Phase I Trial Initiation)CMSD-001

Therapy area: Dermatology, Immunology. Indication: Atopic Dermatitis (Atopic Eczema), Plaque Psoriasis (Psoriasis Vulgaris), Systemic Lupus Erythematosus

full page →CMSD-001 →source: globaldata
›Apr 24, 2026phase 1 results109d agoWroclaw Medical University — viral-specific T-cells (Phase I Trial Results)viral-specific T-cells

Therapy area: Hematological Disorders, Infectious Disease, Oncology. Indication: Aplastic Anemia, Cytomegalovirus (HHV-5) Infections, Hemophagocytic Lymphohistiocytosis, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Refractory Acute Myeloid Leukemia, Viral Infections

full page →viral-specific T-cells →source: globaldata
›Apr 24, 2026phase 2 completion109d agoAlentis Therapeutics AG — lixudebart (Phase II Trial Completion)lixudebart

Therapy area: Genito Urinary System, Immunology. Indication: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis), Glomerulonephritis, Kidney Fibrosis

full page →lixudebart →source: globaldata
›Apr 24, 2026phase iv trial initiation109d agoAll India Institute of Medical Sciences Jodhpur — melatonin (Phase IV Trial Initiation)melatonin

Therapy area: Central Nervous System, Immunology. Indication: Delirium, Inflammation

full page →melatonin →source: globaldata
›Apr 24, 2026phase iv trial initiation109d agoDr Rajendra Prasad Centre for Ophthalmic Sciences — carboxymethylcellulose (Phase IV Trial Initiation)carboxymethylcellulose

Therapy area: Ophthalmology. Indication: Keratoconjunctivitis Sicca (Dry Eye), Unspecified Ophthalmological Disorders

full page →carboxymethylcellulose →source: globaldata